Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (531-540 of 645) with videos related to

Pageof 65
Sort By:
Blood|June 22, 2012
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsSrdan Verstovsek, Hagop M Kantarjian, Zeev Estrov, et al.
Blood Cancer Journal|February 27, 2020
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosisPaola Guglielmelli, Alessandra Carobbio, Elisa Rumi, et al.
Hematological Oncology|June 26, 2020
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinibElisa Rumi, Emanuela Sant'Antonio, Chiara Cavalloni, et al.
Annals of Hematology|July 17, 2018
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda networkPatrizia Zappasodi, Laura Marbello, Erika Borlenghi, et al.
Oncotarget|December 20, 2017
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteriaElisa Rumi, Emanuela Boveri, Marta Bellini, et al.
Haematologica|January 10, 2013
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1Ilaria Ambaglio, Luca Malcovati, Elli Papaemmanuil, et al.
Blood|November 11, 2011
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasmsLuca Arcaini, Silvia Zibellini, Emanuela Boveri, et al.
Blood|November 8, 2019
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasmsChristian A Di Buduo, Vittorio Abbonante, Caroline Marty, et al.
Blood|March 11, 2006
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotypeAndrea Pellagatti, Mario Cazzola, Aristoteles A N Giagounidis, et al.
Blood|August 21, 2009
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosisLuca Malcovati, Matteo G Della Porta, Daniela Pietra, et al.
Pageof 65

Showing results (531-540 of 645) with videos related to

Sort By:
Pageof 65
Blood|June 22, 2012
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsSrdan Verstovsek, Hagop M Kantarjian, Zeev Estrov, et al.
Blood Cancer Journal|February 27, 2020
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosisPaola Guglielmelli, Alessandra Carobbio, Elisa Rumi, et al.
Hematological Oncology|June 26, 2020
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinibElisa Rumi, Emanuela Sant'Antonio, Chiara Cavalloni, et al.
Annals of Hematology|July 17, 2018
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda networkPatrizia Zappasodi, Laura Marbello, Erika Borlenghi, et al.
Oncotarget|December 20, 2017
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteriaElisa Rumi, Emanuela Boveri, Marta Bellini, et al.
Haematologica|January 10, 2013
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1Ilaria Ambaglio, Luca Malcovati, Elli Papaemmanuil, et al.
Blood|November 11, 2011
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasmsLuca Arcaini, Silvia Zibellini, Emanuela Boveri, et al.
Blood|November 8, 2019
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasmsChristian A Di Buduo, Vittorio Abbonante, Caroline Marty, et al.
Blood|March 11, 2006
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotypeAndrea Pellagatti, Mario Cazzola, Aristoteles A N Giagounidis, et al.
Blood|August 21, 2009
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosisLuca Malcovati, Matteo G Della Porta, Daniela Pietra, et al.
Pageof 65